Premium
Successful treatment of methicillin‐resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis
Author(s) -
Ferrin Marianne,
Zuckerman Jonathan B.,
Meagher Alison,
Blumberg Emily A.
Publication year - 2002
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.10062
Subject(s) - medicine , linezolid , cystic fibrosis , staphylococcus aureus , methicillin resistant staphylococcus aureus , exacerbation , vancomycin , antibiotics , antimicrobial , dosing , microbiology and biotechnology , biology , bacteria , genetics
Methicillin‐resistant Staphylococcus aureus (MRSA) is a significant cause of pulmonary infection in patients with cystic fibrosis (CF). Because these organisms are frequently multidrug‐resistant, most patients require intravenous therapy with vancomycin. We report on the first case of successful treatment of a pulmonary exacerbation due to MRSA in a CF patient with a new antimicrobial, linezolid. We demonstrated equivalence of intravenous and oral dosing in this patient, suggesting that oral linezolid may be an excellent alternative to intravenous vancomycin for CF patients infected with MRSA. Pediatr Pulmonol. 2002; 33:221–223. © 2002 Wiley‐Liss, Inc.